Zobrazeno 1 - 10
of 88
pro vyhledávání: '"M Avxentyeva"'
Autor:
E. Pyadushkina, M. Avxentyeva, M. M. Maryanyan, A. S. Mokrova, E. E. Yagnenkova, E.V. Derkach, T. V. Boyarskaya
Publikováno v:
Фармакоэкономика, Vol 13, Iss 3, Pp 225-239 (2020)
Diagnosis-Related Groups (DRG) for the payment for biological therapy were created at the stage of the pilot project and their coefficients of input intensity were not revised since then. The expansion of the range of genetically-engineered biologica
Autor:
M. Avxentyeva, Ivan Stilidi, Yu. A. Ledovskikh, Sergey Gordeev, Z.Z. Mamedli, M. Yu. Fedyanin, A.V. Petrovsky, Alexey Tryakin
Publikováno v:
Practical oncology. 2:91-100
Autor:
M. Avxentyeva, Evgeniya Vasiliyevna Semakova, Alexandr Vladimirovich Zuev, Yulia Anatolievna Ledovskikh, Denis Valerievich Fedyaev, Maria Leonidovna Lazareva, V. V. Omelyanovskiy, Inna Zheleznyakova
Publikováno v:
Medical Technologies. Assessment and Choice (Медицинские технологии. Оценка и выбор). :19-29
Since 2013 a diagnosis-related groups (DRG) model has been introduced for the payment of medical care provided in inpatient settings and the day hospitals in Russia at the federal level. The DRG model is improved annually by the increasing of DRG num
Publikováno v:
Фармакоэкономика, Vol 12, Iss 4, Pp 300-308 (2020)
The aim was to assess the possibility of optimizing the costs of drugs for cancer patients in a subject of the Russian Federation considering the expiration of patent protection period.Materials and methods. The possibility of optimizing the costs of
Publikováno v:
Medical Technologies. Assessment and Choice (Медицинские технологии. Оценка и выбор). :53-61
Purpose of the study. Healthcare budget impact analysis in the Russian Federation of providing adult patients with chronic obstructive pulmonary disease (COPD) with basic therapy for outpatient treatment. Material and methods. The hypothesis of reduc
Publikováno v:
Value in Health. 25:S162
Publikováno v:
Value in Health. 25:S135
Publikováno v:
Medical Technologies. Assessment and Choice (Медицинские технологии. Оценка и выбор). :8-17
Results of the assessment of methodological quality of economic evaluations (EE), submitted to justify the inclusion/exclusion of drugs in the lists of drugs for medical use (list of vital and essential drugs, additional medication supply list and ex
Autor:
Nuriya Musina, Anna Nikitina, M. Avxentyeva, Ksenia Gerasimova, Anastasia Savilova, Filipp Vasilievich Gorkavenko, V. V. Omelyanovskiy
Publikováno v:
Medical Technologies. Assessment and Choice (Медицинские технологии. Оценка и выбор). :63-75
The aim of this study was to estimate the socio-economic burden of lung cancer (LC) in the Russian Federation. Methodology: the social burden of LC is defined as the number of patients newly diagnosed with LC in 2016, those who are followed-up in onc
Publikováno v:
Medical Technologies. Assessment and Choice (Медицинские технологии. Оценка и выбор). :11-18
The article provides the results of the assessment of methodological quality of budget impact analysis (BIA) submitted as a justification for the inclusion/exclusion of drugs into the drugs lists for medical use (Vital and Essential Drug list, List o